skip to main content

Prolactin inhibits apoptosis of ovarian carcinoma cells induced by serum starvation or cisplatin treatment

Asai‐Sato, Mikiko ; Nagashima, Yoji ; Miyagi, Etsuko ; Sato, Ken ; Ohta, Ichiro ; Vonderhaar, Barbara K. ; Hirahara, Fumiki

International Journal of Cancer, 01 July 2005, Vol.115(4), pp.539-544 [Peer Reviewed Journal]

Full text available

Citations Cited by
  • Title:
    Prolactin inhibits apoptosis of ovarian carcinoma cells induced by serum starvation or cisplatin treatment
  • Author: Asai‐Sato, Mikiko ; Nagashima, Yoji ; Miyagi, Etsuko ; Sato, Ken ; Ohta, Ichiro ; Vonderhaar, Barbara K. ; Hirahara, Fumiki
  • Subjects: Ovarian Carcinoma ; Prolactin ; Prolactin Receptor ; Apoptosis ; Cisplatin
  • Is Part Of: International Journal of Cancer, 01 July 2005, Vol.115(4), pp.539-544
  • Description: Prolactin, a peptide hormone essential for the development and function of reproductive organs, is involved in development of breast, prostate and colorectal cancers. However, the role of prolactin on the carcinogenesis of ovarian carcinomas is unclear. In this study, we show that mRNA of prolactin receptor is expressed in 5 out of 9 ovarian carcinoma cell lines, 15 out of 17 cases of surgical samples and all of normal ovarian surface epithelium, while prolactin transcript is detected only in 1 ovarian carcinoma cell line and in 1 of the surgical samples. For the prolactin receptor‐positive ovarian carcinoma cells, exogenous prolactin did not affect the proliferation but markedly inhibited apoptosis. Therefore, actual cell growth was enhanced by prolactin in a dose‐dependent manner. The blocking of prolactin receptor by antibody severely impaired the antiapoptotic and growth‐promoting effects of prolactin. Interestingly, the cisplatin‐induced cell death of the prolactin receptor‐positive cells was significantly inhibited by pretreatment with prolactin. These findings indicate a responsiveness of ovarian carcinomas to prolactin and suggest that the prolactin/prolactin receptor system may be a new therapeutic target of ovarian carcinomas. © 2005 Wiley‐Liss, Inc.
  • Language: English
  • Identifier: ISSN: 0020-7136 ; E-ISSN: 1097-0215 ; DOI: 10.1002/ijc.20810

Searching Remote Databases, Please Wait